Multinational comparative clinical evaluation of two long-acting injectable contraceptive steroids: Norethisterone oenanthate and medroxyprogesterone acetate: 1. Use-effectiveness
References (23)
- et al.
The long-term use of injectable norethisterone enanthate as a contraceptive
Contraception
(1972) Incidence of post-partum deep vein thrombosis in the tropics
Brit. Med. J.
(1974)- et al.
Plasma levels of norethisterone in women receiving norethisterone oenanthate intramuscularly
Contraception
(1975) - et al.
Intramuscular depomedroxyprogesterone acetate for contraception
J. Med. Assoc. Thailand
(1974) Neue Verfahren der hormonalen Contraception
Gynakologic
(1972)Progress Report: DMPA for contraception
Contemp. Obstet. Gynecol.
(1974)Injectable long-acting progestogen contraception: A neglected modality
Am. J. Obstet. Gynecol.
(1974)Experience with Depo Provera as an injectable contraceptive
J. Reprod. Med.
(1974)Depo-Provera: A Review
Contraception
(1975)- et al.
Fertility control with norethindrone enanthate, a long-acting parenteral progestogen
Acta Europaea Fertilitatis
(1973)
Long-acting injectable progestogens in human fertility control
Cited by (72)
An overview of contraception in women with obesity
2023, Best Practice and Research: Clinical Obstetrics and GynaecologyHormonal contraception and obesity
2016, Fertility and SterilityCitation Excerpt :Limited data suggest that pregnancy rates do not change by body weight in depo-medroxyprogesterone acetate (DMPA) users. One multicenter trial of DMPA in 846 women (over 389.5 woman-years) reported a pregnancy rate of 0.7/100 woman-years across all women, and baseline body weight was not related to contraceptive failure (48). However, less than 5% of this population was over 80 kg, so this may not be generalizable to women of higher body weights.
Ectopic pregnancy with use of progestin-only injectables and contraceptive implants: A systematic review
2015, ContraceptionCitation Excerpt :Among 10 studies of DMPA for which the pregnancy rate was reported or could be calculated, rates ranged from 0.1 to 1.7 per 100 woman–years [83,87,89,94,96–98,103–106]. Among studies of NET-EN, rates ranged from 0.3 to 6.6 per 100 woman–years [79,81,83,85,88,90,91,93,96,101–103]. Only three studies — two of NET-EN and one of DMPA — reported any ectopic pregnancies.
Contraception and sexual health in obese women
2015, Best Practice and Research: Clinical Obstetrics and GynaecologyCitation Excerpt :Ovulation suppression is equivalent in obese and thin women for 12 weeks after IM administration [46]. This pharmacodynamic equivalence has also been demonstrated in clinical studies, where there is no difference in IM DMPA failure rates in obese versus normal-weight women [47]. Smaller studies of DMPA-SC also show no difference in ovulation or method failure between obese and normal-weight women [45,48].
To bleed or not to bleed, that is the question
2007, Contraception